U.S., May 20 -- ClinicalTrials.gov registry received information related to the study (NCT07597772) titled 'Preliminary Trial of SNA014 for Pancreatic Cancer' on April 21.
Brief Summary: 68Ga labeled Claudin 18.2 contrast agent combined with PET/CT for pancreatic cancer
Study Start Date: Oct. 01, 2025
Study Type: INTERVENTIONAL
Condition:
Pancreatic Cancer
Intervention:
DRUG: 68Ga-NODAGA-SNA006
Administration
Recruitment Status: RECRUITING
Sponsor: SmartNuclide Biopharma
Published by HT Digital Content Services with permission from Health Daily Digest....